Takeda Secures FDA 510(k) Clearance for HyHub™ and HyHub™ Duo Devices
July 22, 2025
New devices designed to streamline and personalize HYQVIA® administration for patients receiving subcutaneous immune globulin therapy
New devices designed to streamline and personalize HYQVIA® administration for patients receiving subcutaneous immune globulin therapy
Patent strengthens company’s IP portfolio as it expands innovative treatments for chronic pain, oncology, and other high-need conditions
Researchers from the University of Turku and Turku University Hospital, Finland, led by Docent Sami Ventelä and Professor Jukka Westermarck, have developed a diagnostic tool that can revolutionize the treatment guidance of head and neck squamous cell carcinoma.
By sparking the immune system into action, radiation therapy makes certain tumors that resist immunotherapy susceptible to the treatment, leading to positive outcomes for patients, according to new research by investigators at the Johns Hopkins Kimmel Cancer Center Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Netherlands Cancer Institute.
For patients with Parkinson’s disease, changes in their ability to walk can be dramatic. “Parkinson’s gait,” as it is often called, can include changes in step length and asymmetry between legs. This gait dysfunction reduces a person’s mobility, increases fall risk, and significantly impacts a patient’s quality of life.
An antibody treatment developed at Stanford Medicine successfully prepared patients for stem cell transplants without toxic busulfan chemotherapy or radiation, a Phase I clinical trial has shown.
The Global Neurodegeneration Proteomics Consortium (GNPC) has published a series of research papers detailing their efforts to identify patterns in neurodegenerative disease.
In a study conducted in Uganda and published in JAMA Surgery, researchers from Karolinska Institutet evaluated a new surgical method for treating groin hernias in women. The method could become an alternative in resource-limited settings where laparoscopic techniques are not generally available.
AUSTIN, Texas, July 21, 2025 /PRNewswire/ — Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center recently became the first in the nation to implant an FDA-approved novel leadless system that provides cardiac resynchronization therapy to patients with heart failure. Cardiac resynchronization therapy improves the timing of the heart’s contractions, helping to restore the normal rhythm of the heartbeat. The first procedure was recently performed by Robert Canby, M.D., cardiac electrophysiologist at TCAI.
GE HealthCare (Nasdaq: GEHC)+
today announced the commercial launch of its advanced floor-mounted digital X-ray system.